Corbus Pharmaceuticals

Corbus to Start Phase 3 Anabasum Trial in Scleroderma Patients by Year’s End

Ziad2022-11-25T14:05:30-05:00Corbus Pharmaceuticals says a Phase 3 clinical trial of anabasum for diffuse cutaneous scleroderma will start in the fourth quarter of 2017, putting the treatment a step closer toward regulatory approval after a Phase 2 trial that improved patients’ disease. Read more >>

Corbus Pharmaceuticals to Present New Data from Systemic Sclerosis Phase 2 Study of Anabasum at the 15th International Workshop on Scleroderma Research

Ziad2022-11-25T14:05:31-05:00Corbus Pharmaceuticals Holdings, Inc.(NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that recently analyzed skin biopsy histology data from its Phase 2 study of anabasum for the treatment of diffuse cutaneous systemic sclerosis will be presented at the 15th International Workshop on Scleroderma Research. Read more >>

Corbus Pharmaceuticals: Best Places to Work 2017 rankings

Ziad2022-11-25T14:05:41-05:00Corbus Pharmaceuticals has been named one of the Best Places to Work in 2017. Read more >>

Corbus Pharmaceuticals Gets a Buy Rating from Noble Financial

Ziad2022-11-25T14:05:42-05:00Corbus Pharmaceuticals Holdings, Inc. engages in the development and commercialization of novel therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases with clear unmet medical needs. Read more >>

Anabasum: A Potential Treatment for Systemic Sclerosis

Ziad2022-11-25T14:05:53-05:00Corbus CMO Dr. Barbara White, CEO Dr. Yuval Cohen and Dr. Michael Whitfield of Dartmouth University discuss the Phase 2 results of anabasum in systemic sclerosis and its potential to improve the quality of life for patients. Watch now >>

Corbus Pharma outlines U.S. approval path for lead drug

Ziad2022-11-25T14:05:53-05:00The U.S. Food and Drug Administration needs Corbus Pharmaceuticals to show positive data from only one late-stage study on its experimental treatment for scleroderma to support a marketing application, the company said. Read more >>

Inside the small Norwood biotech that’s making investors swoon

Ziad2022-11-25T14:05:53-05:00The top-performing public biotech in Massachusetts over the past year is located in a nondescript brick building with no signage, located along a stretch of highway in Norwood that is better known for its car dealerships than drug developers. Investors in Corbus Pharmaceuticals don’t much seem to mind. The 3-year-old company, situated some 25 miles south of Cambridge and the bustling biotech hub of Kendall Square, has seen its stock price increase more than 400 percent since March 2016, putting it...

Corbus Pharmaceuticals Reports 2016 Financial Results and Provides 2017 Business Update

Ziad2022-11-25T14:05:54-05:00Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) („Corbus” or the „Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today its financial results for the year ended December 31, 2016. Read more >>

Corbus Pharmaceuticals to Present Gene Expression Data from Recent Phase 2 Systemic Sclerosis Study Demonstrating JBT-101 Inhibits Inflammation and Fibrosis Pathways

Ziad2022-11-25T14:05:54-05:00Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Michael L. Whitfield, Ph.D., Professor of Molecular and Systems Biology, Dartmouth Geisel School of Medicine and Scientific Founder of Celdara Medical, LLC, will present data demonstrating JBT-101 treatment of systemic sclerosis patients inhibits gene expression of key regulatory proteins in molecular pathways associated with activating inflammation and fibrosis, while increasing gene expression in...

Corbus Pharmaceuticals to Present at the Cowen and Company 37th Annual Health Care Conference

Ziad2022-11-25T14:05:54-05:00Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Wednesday, March 8 at 10:40 a.m. ET in Boston, MA. Read more >>